class II major histocompatibility complex transactivatorGenealiases: C2TA · CIITAIV · MHC2D1 · MHC2TA · NLRA
Q-omics provides the consensus-scored CIITA profile across patient tissues and cancer cell-line models. CIITA expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CIITA is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CIITA RNA expression shows 17,832 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where CIITA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIITA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIITA survival associations across molecular data types. CIITA RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIITA RNA expression–survival associations across cancer types. High CIITA expression shows unfavorable associations in LGG, but favorable associations in SKCM, HNSC, BLCA, BRCA and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CIITA RNA expression.
This table summarizes CIITA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CIITA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIITA shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, STAD, LIHC and THCA. The KIRC box plot shows higher CIITA RNA expression in tumor versus normal tissue (log2 FC = +1.100, t-test p < 0.001).
This table shows molecular features associated with CIITA in patient tissues and cancer cell lines. In patient samples, CIITA shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CIITA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
